REFERENCES

Armstrong, M., & Vickers, J. (2001). Competitive Price discrimination. *RAND Journal of Economics, 32*(4), 579-605.

Bojer, H. (2004, May 2005). *The Capability Approach to Economic Inequality*. Retrieved December 19, 2004, from http://www.uib.es/congres/ecopub/ecineq/papers/044bojer.pdf: Last access on Sept 19,05

Borenstein, S., & Rose, N. L. (1994). Competition and Price Dispersion in the U.S. Airline Industry. *The Journal of Polictical Economy, 102*(4), 653.

Busse, M., & Rysman, M. (2004, March 2004). *Competition and Price Discrimination in Yellow Pages Advertising*. Retrieved July 18, 2004, from http://econ.bu.edu/rysman/research/yppd.pdf

Clerides, S. K. (2000). Price Discrimination with Differentiated Products: Definition, Theoretical Foundation, Identification. Retrieved July 19, 2004, from http://www.econ.ucy.ac.cy/papers/0009.pdf

Cohen, A. (2004). Identifying Price Discrimination When Product Menus are Endogenous. Retrieved July 29, 2004, from http://www.federalreserve.gov/pubs/feds/2004/200410/200410pap.pdf

Denzau, A. (1992). *Microeconomic analysis : markets and dynamics*: Homewood, Ill. : Richard D. Irwin.

Haidich, A.-B., & Ioannidis, J. P. A. (2004). The Gini coefficieny as a measure for understanding accrual inequalities in multicenter clinical studies. *Journal of Clinical Epidemiology, 57*, 341-348.

Hayes, K. J., & Ross, L. B. (1998). Is Airline Price Dispersion the Result of Careful Planning or Competitive Forces? *Review of Industrial Organization,13(5)* ,523-541.

Gross, A. *(1999) New Regulatory Trends in Thailand's pharmaceutical Market, March 1999 report*. Retrieved May 17, 2003, from http://www.pacificbridgemedical.com

Jenkins, S. P., & Jantti, M. (2005). *Methods for Summarizing and Comparing Wealth Distributions; ISER Working Paper*. Retrieved September 30, 2005, from http://www.iser.essex.ac.uk/pubs/workpaps/pdf/2005-05.pdf

John R. Lott, J., & Roberts, R. D. (1991). A Guide to the Pitfalls of Identifying Price Discrimination. *Economic Inquiry, 29*(1), 14-23.

Lerman, R., & Yitzhaki, S. (1984). A Note on the Calculation and Interpretation of the Gini Index. *Economics Letters, 15*(1984), 363-368.

Litchfield, J. A. (1999). *Inequality: Methods and Tools*. Retrieved Jan 7, 2005, from http://www.worldbank.org/prem/poverty/inequal/methods/litchfie.pdf

Ruby, D. A. (2003). *Price discrimination*. Retrieved August 2, 2004, from http://www.digitaleconomist.com/pd_4010.html

Sakulbumrungsil, R., et al. (2004). Thai National Drug Consumption for the year 2000-2001 (a part of the Research Project of National Health Account : 1994-2004. Bangkok: Health System Research Institution.

Sen, A. (1993). Capability and Well-Being. In M. Nussbaum & A. Sen (Eds.), *The Quality of Life* (pp. 31-53): Clarendon Press: Oxford.

Sen, A. (1997). Editorial: Human Capital and Human Capability. *World Development, 25*(12), 1959-1961.

Stole, L. A. (2003). *Price Discrimination and Imperfect Competition*. Retrieved June 27, 2004, from http://gsblas.uchicago.edu/papers/hio-distrib.pdf

Tradeprot.Org. (1999). Thailand Pharmaceutical Market overview. Retrieved May 14, 2003, from http://www.tradeprot.org/ts/countries/Thailand/mrr/mark0172.html

Xu, K. (2004). *How Has the Literature on Gini's Index Evolved in the Past 80 Years?* Retrieved July, 2004, from http://economics.dal.ca/RePEc/dal/wparch/howgini.pdf

APPENDICES

APPENDICES INSTRUCTION

The appendices instruction aimed to orient the readers how to use the appendices and interpret the exhibited figures with the purpose of price behavior monitoring.

Appendix Direction

The appendices were arranged in harmony with the pharmacological drug groups analyzed in this study. They were ranged from appendix A to E as following.

- APPENDIX A: Agent acting on the Renin-Angiotensin system (ACE Inhibitor)
- APPENDIX B: Agent acting on the Renin-Angiotensin system (Angiotensin II Antagonist)
- APPENDIX C: Beta Blocking Agents
- APPENDIX D: Calcium Channel Blockers
- APPENDIX E: Serum Lipid Reducing Agent

In each pharmacological drug group, drug items (generic name and strength) were alphabetically sorted. The entities, brand belonged to the same drug items, were descending ranked according to the popularity or the market volume: Popular Brand, Brand A, Brand B, Brand C, and so on.

Tools Interpretation

Since there were 4 different types of tools presented in the appendices, this section was then organized in keeping with each type of device as following.

1. First Order Stochastic Approach

Plotting of price/unit on y-axis against the cumulative proportion of quantities on x-axis facilitate the initial comparative exploration. The vertical line from 80% of overall quantities on x-axis was drawn to cut off the graph. The price/unit at cut off points would be interpreted as the majority of product

in a particular market or entities were purchased at the price lower than that determined point. The following figure depicted stochastic approach among brands of an identical drug item in a market.



Figure I. First Order Stochastic Approach

The vertical line from 80% cumulative quantities on x-axis notified that majority of Brand B purchased in that market were cheaper than the Popular Brand and Brand A respectively. This would also imply that there was some degree of price difference across brands traded in that market. The decomposition analysis provided benefits in determining the significance of price difference as described following.

2. Lorenz Curve

Lorenz was the plot between the cumulative of proportion of MAC above total MAC on y-axis and the cumulative of proportion of number of hospitals in that particular market on x-axis.



Figure II Lorenz Dominance Diagram

The Lorenz chart would be interpreted via the area between the Lorenz and equality line and the Lorenz shape. The area between Lorenz curve and equality line would be consistent with the index of inequality. The bigger the area the larger the index identifying the bigger magnitude of price discrimination in the market which also implied the society was worse off from those deals. Greater than 0.5 of Gini or Theil was set as the critical value which was high enough to signal the seriousness of price discrimination. However the 0.45 of Gini for each studied entity were also marked for monitoring. Under the MAC approach, the bigger area was additionally ascertained that the majority of contracts in that market were made at too high prices. This application was apparently exhibited by the map of actual contracts against the estimated price schedule which was subsequently displayed.

The shape of Lorenz had also benefit in pointing out which part of distribution was more inequality. The bigger magnitude of inequality existed in the part where the Lorenz was more distant from equality line. From the following set of figure, figure 1 was the Lorenz shape which reflected the inequality was more intensive at the lower end of distribution.



1 2 3

Figure III The Shape of Lorenz Curve

Figure 2 and 3 were the Lorenz which resulted with the similar indices, but the shape of Lorenz was different. Lorenz of figure 2 implied that the inequality was concentrated in the middle to almost upper tail of distribution, while figure 3 was concentrated in the middle to almost the lower end of distribution.

3. Actual Contracts VS Estimated Price Schedule Map

The vital tool contributed from the MAC approach was the map of actual contracts versus the estimated price schedule of the market. Mapping out the line of price schedule together with the actual contracts facilitated the identification of "could be better" contracts. The actual contracts positioned above the market price schedule would be considered as unfair deals. Not only that, the optimal price for a particular purchasing size of those unfair deals could also be identified based on the market schedule. The cut off value on y-axis for a particular purchasing size on the market price schedule would be the recommended relative price level. This identified Y value or relative price multiplied by the maximum price in the market would yield the recommended purchased price for the particular volume of purchase.



Figure IV Actual Contracts VS Estimated Price Schedule Map

The above figure was the map of actual contracts against the market schedule; there were three series of graph presented. The black line was the theoretical market price schedule, while the gray was also market price schedule but has been adjusted by minimum price. The dot series was the actual contracts, one dot represented one buyer. Dots laid above market price schedule were the buyers who bought the product at too high price judged against their purchasing size. Their optimal prices could be ascertained as described above.



Figure V The Slope of Estimated Price Schedule

The slope of market price schedule implied the sensitivity of prices to purchasing size. The steeper slope (the bigger market MAC) illustrated lower price elasticity: the purchasing size was not utilized as the main source of acquisition capability, but caused the huge price differentiation. The bigger market MAC (the right picture) also implied the small buyer(s) in that

market could obtain the cheap price. The lower market MAC denoted the dealt prices were less sensitive to the variation of purchasing size.

4. Decomposition Analysis

Two types of decomposition analysis were employed. The first was decomposition analysis which the data was partitioned by the market (level of care). The indices resulted from the analysis were within the market and between markets. The between market indices indicated the magnitude of third degree price discrimination, while within the market were the average intensity of first degree price discrimination across each market. Percent contribution to overall discrimination of each type was reported together with indices.

Decomposition Analysis Partition By Market	Index	G(%)	T(%)
	Within	0.562 (62.69)	0.660 (61.93)
	Between	0.334 (37.31)	0.405 (38.07)

The above table could be read as there was the force from discrimination within the market higher than between market discrimination. The product was not priced much different between different markets, in other words, the first degree price discrimination was prioritized to be concerned.

Another type of decomposition analysis was the decomposing data by brands which belonged to the same generic drug item in a particular market. The interpretation would be the same as previously demonstrated. Between indices were then denoted price differences across brands of the same drug item. The bigger the index the bigger the price differences among brands, which implied the less intensity of price competition among brands as illustrated in following table.

Decomposition Analysis Partition By Brand In Primary Market		
	G(%)	T(%)
Within	0.696 (53.18)	1.177 (59.02)
Between	0.613 (46.82)	0.817 (40.98)

Within brand indices signified the magnitude of first degree price discrimination of the same brand among their buyers in a particular market. This table showed the critical level of both types of indices. It would be interpreted that prices of brands belonged to this drug item were not competing each other, they instead differentiated their prices among their own buyers. In another word, their price positioning was different across brands. Under the MAC approach, the critical value of between brands indices additionally signified that majority of contracts in this market were belonged to the expensive brands.

5. List of Abbreviation

Cum prop of MAC stands for the cumulative of the proportion of contracts' MAC above overall MAC in the market.

Cum prop of H stands for the cumulative of the proportion of a hospital above total number of hospital in the market.

CV coefficient of variation equal to the proportion of SD above Pmean.

G Gini coefficient

MAC stands for Miscellaneous Acquisition Capability

n number of hospitals in the market

PB stands for popular brand **of a particular product which was identified by the highest number of purchasers**

Pmin the minimum contract price

Pmax the maximum contract price

Pmean the arithmetic mean of contract price

Qmax	the maximum purchasing size
Qmin	the minimum purchasing size
Qtotal	summation of purchasing size in a market
SD	the standard deviation of contract price
T	Theil Index
WAP	weighted average price by purchasing size

APPENDIX A

APPENDIX A: Agent Acting on the Renin-Angiotensin System(ACE Inhibitor)

A1: Captopril 25 mg -Popular Brand in Tertiary Hospital Market

Tertiary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	1.52	2.50	1.976	0.429	0.217	2.271		
Quantity	156000	5500	80000						
MAC	5		7.24	2.185				0.600	0.698





Appendix A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A2-1: Enalapril 20 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	39	0.21	0.38	0.265	0.029	0.109	0.262	2864100	5000	220000	3.014	0.62	0.771
Secondary	8	0.21	0.34	0.259	0.042	0.162	0.247	2646500	141000	845500	1.071	0.355	0.260
Tetiary	4	0.23	0.29	0.258	0.025	0.097	0.251	1707000	168000	669000	0.168	0.402	0.367







Appendix A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A2-1: Enalapril 20 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market







Decomposition Analysis PartitionByMarket	Index	G(%)	T(%)
	Within	0.562 (62.69)	0.660 (61.93)
	Between	0.334 (37.31)	0.405 (38.07)

APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A2-2: Enalapril 5 mg -Brand A in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	8	0.24	0.28	0.255	0.021	0.081	0.261		
Quantity	1028000	12000	300000						
MAC	8		3.854	2.409				0.375	0.470





APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A2-3: Enalapril 5 mg -Brand B in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	8	0.22	0.65	0.313	0.169	0.542	0.278		
Quantity	905000	25000	483000						
MAC	8		20.930	14.933				0.280	0.263





APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A2-4: Enalapril 5 mg -Brand C in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	0.60	1.08	0.858	0.238	0.278	0.860		
Quantity	350000	30000	110000						
MAC	5		2.155	0.896				0.570	0.754





APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A2: Enalapril 5 mg; Popular Brand, Brand A, Brand B, Brand C

Brand	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Popular	39	0.21	0.38	0.265	0.029	0.109	0.262	2864100	5000	220000	3.014	0.62	0.771
Brand A	8	0.24	0.28	0.255	0.021	0.081	0.261	1028000	12000	300000	2.409	0.375	0.470
Brand B	8	0.22	0.65	0.313	0.169	0.542	0.278	905000	25000	483000	14.933	0.280	0.263
Brand C	5	0.60	1.08	0.858	0.238	0.278	0.860	350000	30000	110000	0.896	0.570	0.754





APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A2: Enalapril 5 mg; Popular Brand, Brand A, Brand B, Brand C





Decompositon Analysis PartitionByBrand InPrimaryMarket		
	G(%)	T(%)
Within	0.538 (57.79)	0.662 (63.39)
Between	0.393 (42.21)	0.382 (36.61)

Appendix A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A3-1: Enalapril 20 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	32	0.62	0.98	0.728	0.098	0.134	0.729	765500	500	90000	6.022	0.753	1.344
Secondary	8	0.54	1.80	0.889	0.425	0.478	0.884	1135500	1500	485000	5.004	0.478	0.433
Tetiary	4	0.59	0.79	0.678	0.088	0.129	0.686	1090000	130000	395000	0.323	0.523	0.548







Appendix A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A3-1: Enalapril 20 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market







Decomposition Analysis PartitionByMarket	Index	G(%)	T(%)
	Within	0.682 (67.18)	1.106 (73.17)
	Between	0.333 (32.82)	0.405 (26.83)

APPENDIX A: Agent Acting on the Renin-Angiotensin System(ACE Inhibitor)

A3-2: Enalapril 20 mg -Brand A in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	0.60	2.50	1.000	0.839	0.839	0.720		
Quantity	68700	3000	40000						
MAC	5		9.207	4.932				0.426	0.394





APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A3-3: Enalapril 20 mg -Brand B in Secondary Hospital Market

Secondary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	0.40	1.68	0.795	0.594	0.747	0.817		
Quantity	321000	20000	172000						
MAC	4		9.603	5.081				0.459	0.518





APPENDIX A: Agent Acting on the Renin-Angiotensin System(ACE Inhibitor)

A3-4: Enalapril 20 mg -Brand C in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	0.64	1.70	1.292	0.530	0.410	1.432		
Quantity	135000	6000	45000						
MAC	5		5.748	2.307				0.598	0.895





APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A3: Enalapril 20 mg; Popular Brand, Brand A, Brand C

Brand	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Popular	32	0.62	0.98	0.728	0.098	0.134	0.729	765500	500	90000	6.022	0.753	1.344
Brand A	5	0.60	2.50	1.000	0.839	0.839	0.720	68700	3000	40000	4.932	0.426	0.394
Brand C	5	0.64	1.70	1.292	0.530	0.410	1.432	135000	6000	45000	2.307	0.598	0.895





APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A3: Enalapril 20 mg; Popular Brand, Brand A, Brand C





Decompositon Analysis PartitionByBrand InPrimaryMarket		
	G(%)	T(%)
Within	0.696 (53.18)	1.177 (59.02)
Between	0.613 (46.82)	0.817 (40.98)

APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A4: Fosinopril 10 mg -Single Brand in Tertiary Hospital Market

Tertiary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	7	11.44	13.17	12.381	0.612	0.049	12.452		
Quantity	156000	2400	45000						
MAC	7		0.461	0.255				0.376	0.310





APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A5: Perindopril 4 mg -Single Brand in Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Secondary	13	11.67	13.91	12.985	0.648	0.049	12.967	381030	9000	57150	0.212	0.471	0.402
Tetiary	10	12.29	13.91	12.946	0.480	0.037	12.933	234300	3000	57000	0.316	0.425	0.333







APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A5: Perindopril 4 mg -Single Brand in Secondary, Tertiary Hospital Market





APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A6: Quinapril 5 mg -Single Brand in Secondary Hospital Market

Secondary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	8.01	9.28	8.950	0.627	0.070	9.224		
Quantity	126028	3920	60760						
MAC	4		2.281	0.572				0.748	1.364





APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A7: Quinapril 20 mg- Single Brand in Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Secondary	8	13.78	16.81	14.256	1.033	0.072	14.571	228928	2352	52920	1.276	0.620	0.792
Tetiary	6	13.91	15.50	14.175	0.649	0.046	14.151	258132	7840	68012	0.782	0.167	0.182







APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A7: Quinapril 20 mg- Single Brand in Secondary, Tertiary Hospital Market





APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A8: Ramipril 2.5 mg- Single Brand in Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Secondary	4	8.5	9.1	8.950	0.3	0.034	9.084	187900	5000	119900	0.409	0.75	1.386
Tetiary	7	7.2	9.74	8.834	0.805	0.091	8.752	391500	12000	150000	0.420	0.464	0.446







APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A8: Ramipril 2.5 mg- Single Brand in Secondary, Tertiary Hospital Market





APPENDIX A: Agent acting on the Renin-Angiotensin system(ACE Inhibitor)

A9: Ramipril 5 mg -Single Brand in Tertiary Hospital Market

Tertiary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	12.03	15.36	13.978	1.463	0.105	13.957		
Quantity	85708	9240	34720						
MAC	4		0.422	0.220				0.468	0.546





APPENDIX B

APPENDIX B: Agent acting on the Renin-Angiotensin system(Angiotensin II Antagonist)

B1: Losartan 50 mg -Single Brand in Secondary Hospital Market

Secondary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	23.54	28.15	24.693	2.305	0.093	23.811		
Quantity	66300	3900	42300						
MAC	4		0.901	0.675				0.250	0.288





APPENDIX B: Agent acting on the Renin-Angiotensin system(Angiotensin II Antagonist)

B2: Losartan+HCTZ 100+25 mg -Single Brand in Secondary Hospital Market

Secondary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	25.68	26.75	25.948	0.535	0.021	25.856		
Quantity	54600	9000	20700						
MAC	4		0.080	0.060				0.250	0.288





APPENDIX B: Agent acting on the Renin-Angiotensin system(Angiotensin II Antagonist)

B3: Valsartan 80 mg -Single Brand in Tertiary Hospital Market

Tertiary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	17.07	23.96	21.750	3.193	0.147	22.405		
Quantity	95984	7504	58800						
MAC	4		2.657	0.701				0.711	1.143





APPENDIX B: Agent acting on the Renin-Angiotensin system(Angiotensin II Antagonist)

B4: Valsartan 160 mg -Single Brand in Secondary and Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Secondary	7	31.34	45.13	36.347	4.649	0.128	34.297	149380	4200	73500	2.492	0.490	0.462
Tetiary	7	22.00	45.86	31.193	7.359	0.236	29.339	217168	3920	84000	3.454	0.650	0.820







APPENDIX B: Agent acting on the Renin-Angiotensin system(Angiotensin II Antagonist)

B4: Valsartan 160 mg -Single Brand in Secondary and Tertiary Hospital Market





APPENDIX B: Agent acting on the Renin-Angiotensin system(Angiotensin II Antagonist)

B5: Valsartan+HCTZ 80+12.5 mg -Single Brand in Tertiary Hospital Market

Tertiary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	24.17	30.00	25.738	2.845	0.111	24.598		
Quantity	120512	6664	47040						
MAC	4		0.391	0.254				0.327	0.313





APPENDIX C

APPENDIX C: Beta Blocking Agents

C1: Atenolol 50 mg; Popular Brand, Brand A, Brand B in Primary Hospital Market

Brand	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Popular	28	0.20	1.59	0.571	0.283	0.495	0.623	1225300	2800	145000	11.191	0.606	0.732
Brand A	16	0.32	0.80	0.591	0.145	0.245	0.607	946900	3000	290000	5.394	0.553	0.584
Brand B	5	0.41	1.20	0.792	0.289	0.365	0.833	280000	17500	100000	1.087	0.308	0.255





APPENDIX C: Beta Blocking Agents

C1: Atenolol 50 mg; Popular Brand, Brand A, Brand B in Primary Hospital Market





Decompositon Analysis PartitionByBrand InPrimaryMarket		
	G(%)	T(%)
Within	0.558 (58.83)	0.635 (60.17)
Between	0.391 (41.17)	0.420 (39.83)

APPENDIX C: Beta Blocking Agents

C1-1: Atenolol 50 mg -Popular Brand in Primary, Secondary and Tertiary Hospital Markets







Decomposition Analysis PartitionByMarket	Index	G(%)	T(%)
	Within	0.542 (52.79)	0.597 (53.78)
	Between	0.485 (47.21)	0.513 (46.22)

APPENDIX C: Beta Blocking Agents

C1-1: Atenolol 50 mg -Popular Brand in Primary, Secondary and Tertiary Hospital Markets

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	28	0.2	1.59	0.571	0.283	0.495	0.623	1225300	2800	145000	11.191	0.606	0.732
Secondary	9	0.31	0.52	0.403	0.088	0.218	0.402	3347500	120000	1350000	1.613	0.512	0.508
Tetiary	9	0.33	1.73	0.680	0.411	0.605	0.519	3742000	105000	1540000	7.694	0.374	0.265







APPENDIX C: Beta Blocking Agents

C1-2: Atenolol 50 mg -Brand A in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	16	0.32	0.80	0.591	0.145	0.245	0.607		
Quantity	946900	3000	290000						
MAC	16	0.000	21.571	5.394				0.553	0.584





APPENDIX C: Beta Blocking Agents

C1-3: Atenolol 50 mg -Brand B in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	0.41	1.20	0.792	0.289	0.365	0.833		
Quantity	280000	17500	100000						
MAC	5	0.000	1.718	1.087				0.308	0.255





APPENDIX C: Beta Blocking Agents

C2-1: Atenolol 100 mg -Popular Brand in Primary, Secondary and Tertiary Hospital Markets







Decomposition Analysis PartitionByMarket	Index	G(%)	T(%)
	Within	0.548 (56.74)	0.574 (56.74)
	Between	0.418 (43.26)	0.438 (43.26)

APPENDIX C: Beta Blocking Agents

C2-1: Atenolol 100 mg -Popular Brand in Primary, Secondary and Tertiary Hospital Markets

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	11	0.59	1.5	1.084	0.256	0.237	1.101	340500	7500	100000	2.558	0.612	0.689
Secondary	9	0.57	2.95	1.112	0.741	0.666	0.919	887000	10000	354000	12.894	0.548	0.573
Tetiary	6	0.6	1.2	0.753	0.228	0.302	0.681	1404500	80000	419500	1.500	0.430	0.365







APPENDIX C: Beta Blocking Agents

C2-2: Atenolol 100 mg -Brand A in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	0.57	1.44	1.022	0.416	0.407	1.055		
Quantity	208200	8200	97000						
MAC	5	0.000	4.087	1.892				0.518	0.602





APPENDIX C: Beta Blocking Agents

C3: Bisoprolol 5 mg -Single Brand in Tertiary Hospital Market

Tertiary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	7	7.38	8.68	7.936	0.411	0.052	7.617		
Quantity	472000	8000	233000						
MAC	7	0.000	2.267	1.233				0.419	0.391





APPENDIX C: Beta Blocking Agents

C4: Carvidilol 12.5 mg -Single Brand in Tertiary Hospital Market

Tertiary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	19.68	19.69	19.688	0.005	0.000	19.690		
Quantity	62500	2000	45000						
MAC	4	0.000	0.011	0.003				0.750	1.386





APPENDIX C: Beta Blocking Agents

C5: Carvidilol 25 mg -Single Brand in Secondary, Tertiary Hospital Market





APPENDIX C: Beta Blocking Agents

C5: Carvidilol 25 mg -Single Brand in Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Secondary	4	24.61	24.61	24.61	0.000	0.000	24.61	64500	500	32000	0.000	0.000	0.000
Tetiary	7	24.61	26.33	24.85571	0.650	0.026	24.8014	132100	7000	42000	0.347	0.143	0.154







APPENDIX C: Beta Blocking Agents

C6: Propanolol 10 mg -Popular Brand, Brand A, Brand B in Primary Hospital Market

Brand	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Popular	111	0.39	0.4	0.39	0.001	0.002	0.389	8919000	7500	380000	1.689	0.009	0.009
Brand A	13	0.19	0.39	0.352	0.057	0.161	0.344	1090000	10000	290000	0.639	0.776	1.411
Brand B	4	0.20	0.34	0.273	0.068	0.250	0.274	501000	100000	160000	0.327	0.520	0.562





APPENDIX C: Beta Blocking Agents

C6: Propanolol 10 mg -Popular Brand, Brand A, Brand B in Primary Hospital Market





Decompositon Analysis PartitionByBrand InPrimaryMarket		
	G(%)	T(%)
Within	0.103 (15.20)	0.169 (19.56)
Between	0.573 (84.80)	0.694 (80.44)

APPENDIX C: Beta Blocking Agents

C6-1: Propanolol 10 mg -Popular Brand Pack Size 10x50 in Primary, Secondary and Tertiary Hospital Markets







APPENDIX C: Beta Blocking Agents

C6-1: Propanolol 10 mg -Popular Brand Pack Size 10x50 in Primary, Secondary and Tertiary Hospital Markets

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	111	0.39	0.40	0.39	0.001	0.002	0.389	8919000	7500	380000	1.689	0.009	0.009
Secondary	19	0.39	0.39	0.390	0.000	0.000	0.389	4197000	75000	490000	0.000	0.000	0.000
Tetiary	9	0.39	0.39	0.390	0.000	0.000	0.389	3231000	130000	505000	0.000	0.000	0.000







APPENDIX C: Beta Blocking Agents

C6-2: Propanolol 10 mg -Popular Brand (Propanolol-GPO) Pack Size 1x1000 in Primary, Secondary and Tertiary Hospital Markets







APPENDIX C: Beta Blocking Agents

C6-2: Propanolol 10 mg -Popular Brand Pack Size 1x1000 in Primary, Secondary and Tertiary Hospital Markets

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	27	0.32	0.32	0.32	0.000	0.000	0.321	1895000	5000	210000	0.000	0.000	0.000
Secondary	7	0.32	0.32	0.320	0.000	0.000	0.321	1573000	50000	590000	0.000	0.000	0.000
Tetiary	4	0.32	0.32	0.320	0.000	0.000	0.321	2205000	280000	720000	0.000	0.000	0.000







APPENDIX C: Beta Blocking Agents

C6-3: Propanolol 10 mg -Brand A in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	13	0.19	0.39	0.352	0.057	0.161	0.344		
Quantity	1090000	10000	290000						
MAC	13	0.000	5.958	0.639				0.776	1.411





APPENDIX C: Beta Blocking Agents

C6-4: Propanolol 10 mg -Brand B in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	0.20	0.34	0.273	0.068	0.250	0.274		
Quantity	501000	100000	160000						
MAC	4	0.000	0.765	0.327				0.520	0.562





APPENDIX C: Beta Blocking Agents

C7-1: Propanolol 40 mg -Popular Brand Pack Size 10x50 in Primary, Secondary and Tertiary Hospital Markets



APPENDIX C: Beta Blocking Agents

C7-1: Propanolol 40 mg -Popular Brand Pack Size 10x50 in Primary, Secondary and Tertiary Hospital Markets

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	23	0.45	0.45	0.45	0.000	0.000	0.4494	938000	5000	106000	0.000	0.000	0.000
Secondary	6	0.45	0.45	0.450	0.000	0.000	0.4494	961000	19000	450000	0.000	0.000	0.000
Tetiary	5	0.45	0.45	0.450	0.000	0.000	0.449323	623000	70000	220000	0.000	0.000	0.000







APPENDIX C: Beta Blocking Agents

C7-2: Propanolol 40 mg -Popular Brand Pack Size 1x1000 in Primary, Secondary and Tertiary Hospital Markets

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	23	0.45	0.45	0.45	0.000	0.000	0.4494	938000	5000	106000	0.000	0.000	0.000
Secondary	6	0.45	0.45	0.450	0.000	0.000	0.4494	961000	19000	450000	0.000	0.000	0.000
Tetiary	5	0.45	0.45	0.450	0.000	0.000	0.449323	623000	70000	220000	0.000	0.000	0.000



APPENDIX C: Beta Blocking Agents

C7-2: Propanolol 40 mg -Popular Brand Pack Size 1x1000 in Primary, Secondary and Tertiary Hospital Markets







APPENDIX C: Beta Blocking Agents

C7-3: Propanolol 40 mg -Brand A in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	0.54	0.61	0.559	0.036	0.064	0.553		
Quantity	87500	15000	35000						
MAC	4	0.000	0.296	0.196				0.317	0.305





APPENDIX C: Beta Blocking Agents

C8: Metoprolol 100 mg -Popular Brand in Secondry Hospital Market

Secondary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	0.77	1.6	1.052	0.373	0.355	0.897		
Quantity	222500	10500	100000						
MAC	4	0.000	2.781	1.531				0.431	0.450





APPENDIX D

APPENDIX D: Calcium Channel Blockers

D1-1: Amlodipine 5 mg -Popular Brand in Primary, Secondary Hospital Market





APPENDIX D: Calcium Channel Blockers

D1-1: Amlodipine 5 mg -Popular Brand in Primary, Secondary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	9	5.00	6.71	5.979	0.491	0.082	6.065	170000	1500	107000	3.592	0.573	0.631
Secondary	6	5.00	6.00	5.667	0.516	0.091	5.814	209500	12500	64000	0.311	0.667	1.099







APPENDIX D: Calcium channel blockers

D2-1: Amlodipine 10 mg -Popular Brand in Tertiary Hospital Market

Tertiary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	23.90	24.00	23.980	0.045	0.002	23.981		
Quantity	179600	20000	56000						
MAC	5	0.000	0.007	0.001				0.800	1.609





APPENDIX D: Calcium channel blockers

D2-2: Amlodipine 10 mg -Brand A in Tertiary Hospital Market

Tertiary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	8.00	11.00	9.500	1.291	0.136	8.929		
Quantity	196000	21000	88000						
MAC	4	0.000	0.321	0.226				0.283	0.292





APPENDIX D: Calcium Channel Blockers

D3-1: Diltiazem 30 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market







Decomposition Analysis PartitionByMarket	Index	G(%)	T(%)
	Within	0.462 (49.61)	0.494 (50.15)
	Between	0.470 (50.39)	0.492 (49.85)

APPENDIX D: Calcium Channel Blockers

D3-1: Diltiazem 30 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	4	0.64	1.77	1.0575	0.539	0.510	1.192	37500	2000	27000	6.968	0.489	0.627
Secondary	5	0.63	1.18	0.766	0.236	0.308	0.701	317500	9500	143000	1.208	0.455	0.400
Tetiary	4	0.63	1.70	1.065	0.524	0.492	0.985	271600	26000	103000	0.928	0.444	0.480



APPENDIX D: Calcium Channel Blockers

D3-2: Diltiazem 30 mg -Brand A in Secondary, Tertiary Hospital Market





APPENDIX D: Calcium Channel Blockers

D3-2: Diltiazem 30 mg -Brand A in Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Secondary	8	0.72	1.20	0.975	0.172	0.177	1.005	347000	17000	80000	0.613	0.476	0.419
Tetiary	5	0.67	1.60	0.964	0.422	0.438	1.252	335500	26500	185000	3.832	0.348	0.342







APPENDIX D: Calcium channel blockers

D4: Diltiazem 90 mg -Popular Brand in Secondary Hospital Market

Secondary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	10.00	12.00	10.500	1.000	0.095	10.010		
Quantity	163500	800	95700						
MAC	4	0.000	0.582	0.436				0.250	0.288





APPENDIX D: Calcium Channel Blockers

D5: Diltiazem 120 mg -Popular Brand in Secondary, Tertiary Hospital Market





APPENDIX D: Calcium Channel Blockers

D5: Diltiazem 120 mg -Popular Brand in Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Secondary	4	13.00	14.81	13.908	0.739	0.053	14.049	26300	3000	13000	0.446	0.525	0.539
Tetiary	4	13.91	13.91	13.910	0.000	0.000	13.910	127000	11000	53000	0.000	0.000	0.000







APPENDIX D: Calcium Channel Blockers

D6: Felodipine 5 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market







Decomposition Analysis PartitionByMarket	Index	G(%)	T(%)
	Within	0.663 (61.03)	0.882 (66.59)
	Between	0.424 (38.97)	0.443 (33.41)

APPENDIX D: Calcium Channel Blockers

D6: Felodipine 5 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	6	13.36	15.27	13.692	0.773	0.056	13.449	53610	1560	22350	0.506	0.572	0.645
Secondary	20	12.16	16.29	13.381	0.850	0.064	13.245	912240	3000	106260	1.883	0.630	0.758
Tetiary	15	12.27	13.38	13.099	0.438	0.033	12.888	1461450	21600	398400	0.078	0.744	1.142







APPENDIX D: Calcium channel blockers

D7: Manidipine 20 mg -Single Brand in Tertiary Hospital Market

Tertiary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	9	13.08	13.52	13.454	0.149	0.011	13.468		
Quantity	552700	7000	210000						
MAC	9	0.000	0.183	0.024				0.858	1.794





APPENDIX D: Calcium channel blockers

D8: Nicardipine 2mg/2ml amp.-Single Brand in Secondary Hospital Market

Secondary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	8	74.90	86.40	81.160	4.588	0.057	83.006		
Quantity	810	20	310						
MAC	8	0.000	1.476	0.527				0.572	0.620





APPENDIX D: Calcium channel blockers

D9: Nicardipine 10mg/10ml -Single Brand in Tertiary Hospital Market

Tertiary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	304.85	330.63	313.220	11.748	0.038	311.892		
Quantity	1480	40	1060						
MAC	4	0.000	1.819	0.927				0.486	0.614





APPENDIX D: Calcium Channel Blockers

D10-1: Nifedipine 5 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market







Decomposition Analysis PartitionByMarket	Index	G(%)	T(%)
	Within	0.672 (52.60)	0.972 (55.07)
	Between	0.606 (47.40)	0.793 (44.93)

APPENDIX D: Calcium Channel Blockers

D10-1: Nifedipine 5 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	28	0.60	1.70	0.843	0.229	0.272	0.793	711400	300	247700	82.238	0.765	1.204
Secondary	7	0.51	1.75	0.893	0.448	0.502	0.874	381300	6000	150000	5.437	0.492	0.482
Tetiary	5	0.53	0.85	0.660	0.124	0.188	0.615	257200	13200	104000	0.768	0.408	0.364







APPENDIX D: Calcium channel blockers

D10-2: Nifedipine 5 mg -Brand A in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	16	0.50	1.63	0.682	0.298	0.437	0.643		
Quantity	359500	2500	60000						
MAC	16	0.000	23.199	6.023				0.539	0.526





APPENDIX D: Calcium channel blockers

D10-3: Nifedipine 5 mg -Brand B in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	0.53	0.80	0.592	0.117	0.197	0.539		
Quantity	103500	2000	70000						
MAC	5	0.000	10.491	6.586				0.365	0.378





APPENDIX D: Calcium Channel Blockers

D10: Nifedipine 5 mg; Popular Brand, Brand A, Brand B

Brand	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Popular	28	0.60	1.70	0.843	0.229	0.272	0.793	711400	300	247700	82.238	0.765	1.204
Brand A	16	0.50	1.63	0.682	0.298	0.437	0.643	359500	2500	60000	6.023	0.539	0.526
Brand B	5	0.53	0.80	0.592	0.117	0.197	0.539	103500	2000	70000	6.586	0.365	0.378





APPENDIX D: Calcium Channel Blockers

D10: Nifedipine 5 mg; Popular Brand, Brand A, Brand B





Decompositon Analysis PartitionByBrand InPrimaryMarket		
	G(%)	T(%)
Within	0.650 (53.00)	0.898 (56.11)
Between	0.577 (47.00)	0.702 (43.89)

APPENDIX D: Calcium Channel Blockers

D11-1: Nifedipine 10 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market







Decomposition Analysis PartitionByMarket	Index	G(%)	T(%)
	Within	0.470 (43.51)	0.412 (33.79)
	Between	0.610 (56.49)	0.808 (66.21)

APPENDIX D: Calcium Channel Blockers

D11-1: Nifedipine 10 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	45	0.45	2.5	0.848	0.293	0.345	0.791	2246100	2500	235000	9.817	0.469	0.397
Secondary	4	0.57	1.15	0.845	0.240	0.284	0.951	419400	22000	222400	2.679	0.568	0.655
Tetiary	5	0.64	1.15	0.790	0.213	0.270	0.746	275000	10000	120000	0.984	0.400	0.356







APPENDIX D: Calcium Channel Blockers

D11-2: Nifedipine 10 mg -Brand A in Primary, Secondary Hospital Market





APPENDIX D: Calcium Channel Blockers

D11-2: Nifedipine 10 mg -Brand A in Primary, Secondary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	30	0.53	1.65	0.734	0.244	0.332	0.693	1871000	8000	200000	6.054	0.533	0.49
Secondary	4	0.59	1.80	0.900	0.600	0.667	0.833	537500	6500	340000	15.906	0.700	1.058







APPENDIX D: Calcium Channel Blockers

D11-3: Nifedipine 10 mg -Brand B in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	13	0.57	0.86	0.645	0.110	0.170	0.625		
Quantity	474000	8000	105000						
MAC	13	0.000	4.946	2.072				0.512	0.484





APPENDIX D: Calcium Channel Blockers

D11-4: Nifedipine 10 mg -Brand C in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	8	1.49	3.10	2.146	0.528	0.246	2.008		
Quantity	556000	18000	270000						
MAC	8	0.000	7.414	3.189				0.459	0.388





APPENDIX D: Calcium Channel Blockers

D11: Nifedipine 10 mg; Popular Brand, Brand A, Brand B, Brand C

Brand	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Popular	45	0.45	2.5	0.848	0.293	0.345	0.791	2246100	2500	235000	9.817	0.469	0.397
Brand A	30	0.53	1.65	0.734	0.244	0.332	0.693	1871000	8000	200000	6.054	0.533	0.490
Brand B	13	0.57	0.86	0.645	0.110	0.170	0.625	474000	8000	105000	2.072	0.512	0.484
Brand C	8	1.49	3.10	2.146	0.528	0.246	2.008	556000	18000	270000	3.189	0.459	0.388





APPENDIX D: Calcium Channel Blockers

D11: Nifedipine 10 mg; Popular Brand, Brand A, Brand B, Brand C





Decompositon Analysis PartitionByBrand InPrimaryMarket		
	G(%)	T(%)
Within	0.494 (47.44)	0.437 (42.38)
Between	0.547 (52.56)	0.594 (57.62)

APPENDIX D: Calcium Channel Blockers

D12-1: Nifedipine 20 mg -Popular Brand in Primary, Secondary Hospital Market





APPENDIX D: Calcium Channel Blockers

D12-1: Nifedipine 20 mg -Popular Brand in Primary, Secondary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	17	1.37	5.00	2.506	0.990	0.395	2.059	793400	6000	146000	4.431	0.459	0.386
Secondary	7	1.68	3.50	2.381	0.669	0.281	2.173	2251500	30000	786000	1.867	0.448	0.377







APPENDIX D: Calcium Channel Blockers

D12-2: Nifedipine 20 mg -Brand A in Primary, Secondary Hospital Market





APPENDIX D: Calcium Channel Blockers

D12-2: Nifedipine 20 mg -Brand A in Primary, Secondary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	16	2.20	3.50	2.883	0.483	0.168	2.656	637600	2000	210000	4.081	0.656	0.806
Secondary	6	1.74	3.03	2.347	0.448	0.191	2.08	757500	54000	344000	0.966	0.261	0.206







APPENDIX D: Calcium Channel Blockers

D12-3: Nifedipine 20 mg -Brand B in Primary, Tertiary Hospital Market





APPENDIX D: Calcium Channel Blockers

D12-3: Nifedipine 20 mg -Brand B in Primary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	10	2.2	3.5	2.960	0.458	0.155	3.177	247950	9000	114000	1.962	0.494	0.465
Tertiary	6	1.8	2.4	2.052	0.234	0.114	1.994	752460	27000	346500	1.144	0.539	0.571







APPENDIX D: Calcium Channel Blockers

D12-4: Nifedipine 20 mg -Brand C in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	10	1.89	2.00	1.963	0.045	0.023	1.948		
Quantity	678100	20000	169600						
MAC	10	0.000	0.453	0.105				0.737	1.154





APPENDIX D: Calcium Channel Blockers

D12-5: Nifedipine 20 mg -Brand D in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	9	5.00	8.00	6.596	0.866	0.131	6.672		
Quantity	161100	2000	56600						
MAC	9	0.000	13.301	2.108				0.713	1.087





APPENDIX D: Calcium Channel Blockers

D12: Nifedipine 20 mg; Popular Brand, Brand A, Brand B, Brand C, Brand D

Brand	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Popular	17	1.37	5.00	2.506	0.990	0.395	2.059	793400	6000	146000	4.431	0.459	0.386
Brand A	16	2.20	3.50	2.883	0.483	0.168	2.656	637600	2000	210000	4.081	0.656	0.806
Brand B	10	2.2	3.5	2.960	0.458	0.155	3.177	247950	9000	114000	1.962	0.494	0.465
Brand C	10	1.89	2.00	1.963	0.045	0.023	1.948	678100	20000	169600	0.105	0.737	1.154
Brand D	9	5.00	8.00	6.596	0.866	0.131	6.672	161100	2000	56600	2.108	0.713	1.087





APPENDIX D: Calcium Channel Blockers

D12: Nifedipine 20 mg; Popular Brand, Brand A, Brand B, Brand C, Brand D





Decompositon Analysis PartitionByBrand InPrimaryMarket		
	G(%)	T(%)
Within	0.597 (63.85)	0.733 (72.12)
Between	0.338 (36.15)	0.283 (27.88)

APPENDIX D: Calcium Channel Blockers

D13: Nifedipine 30 mg -Single Brand in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	8	17.09	18.90	17.339	0.631	0.036	17.286		
Quantity	521640	4500	138000						
MAC	8	0.000	3.033	0.905				0.627	0.806





APPENDIX D: Calcium Channel Blockers

D14-1: Verapamil 40 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market







Decomposition Analysis PartitionByMarket	Index	G(%)	T(%)
	Within	0.444 (57.14)	0.363 (47.25)
	Between	0.333 (42.86)	0.405 (52.75)

APPENDIX D: Calcium Channel Blockers

D14-1: Verapamil 40 mg -Popular Brand in Primary, Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	10	0.84	1.80	1.296	0.347	0.268	1.293	57000	3500	10000	0.769	0.421	0.340
Secondary	12	0.84	2.00	1.400	0.313	0.224	1.374	285000	7000	64500	1.432	0.413	0.298
Tetiary	8	0.70	1.90	1.250	0.408	0.326	1.277	451500	25000	112000	1.288	0.521	0.490







APPENDIX D: Calcium Channel Blockers

D14-2: Verapamil 40 mg -Brand A in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	9	0.66	2.00	1.162	0.570	0.490	1.570		
Quantity	89000	2000	50000						
MAC	9	0.000	20.996	9.597				0.427	0.373





APPENDIX D: Calcium channel blockers

D14-3: Verapamil 40 mg -Brand B in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	0.85	1.74	1.113	0.424	0.381	1.153		
Quantity	8500	1000	2750						
MAC	4	0.000	1.970	0.838				0.443	0.423





APPENDIX D: Calcium Channel Blockers

D14: Verapamil 40 mg; Popular Brand, Brand A, Brand B

Brand	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Popular	10	0.84	1.80	1.296	0.347	0.268	1.293	57000	3500	10000	0.769	0.421	0.340
Brand A	9	0.66	2.00	1.162	0.570	0.490	1.570	89000	2000	50000	9.597	0.427	0.373
Brand B	4	0.85	1.74	1.113	0.424	0.381	1.153	8500	1000	2750	0.838	0.443	0.423





APPENDIX D: Calcium Channel Blockers

D14: Verapamil 40 mg; Popular Brand, Brand A, Brand B





Decompositon Analysis PartitionByBrand InPrimaryMarket		
	G(%)	T(%)
Within	0.427 (41.19)	0.367 (31.31)
Between	0.609 (58.81)	0.806 (68.69)

APPENDIX D: Calcium Channel Blockers

D15: Verapamil 240 mg Dragee SR -Single Brand in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	18.91	21.44	20.904	1.115	0.053	20.069		
Quantity	23850	1200	12750						
MAC	5	0.000	0.126	0.034				0.644	0.809





APPENDIX E

APPENDIX E: Serum Lipid Reducing Agent

E1: Atovastatin 10 mg -Single Brand in Secondary, Tertiary Hospital Market





APPENDIX E: Serum Lipid Reducing Agent

E1: Atovastatin 10 mg -Single Brand in Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Secondar	14	36.24	43.87	37.800	2.164	0.057	37.262	450000	900	96500	2.120	0.663	0.866
Tetiary	8	36.11	37.81	36.686	0.485	0.013	36.597	695900	12500	194500	0.110	0.470	0.397







APPENDIX E: Serum Lipid Reducing Agent

E2: Atovastatin 20 mg -Single Brand in Primary, Tertiary Hospital Market





APPENDIX E: Serum Lipid Reducing Agent

E2: Atovastatin 20 mg -Single Brand in Primary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	4	58.42	65.27	60.618	3.135	0.052	59.381	17300	600	11500	6.004	0.457	0.513
Tetiary	4	50.59	55.64	53.643	2.174	0.041	51.682	240200	8000	167700	0.110	0.276	0.291







APPENDIX E: Serum Lipid Reducing Agent

E3-1: Gemfibrozil 300mg -Popular Brand in Primary, Secondary and Tertiary Hospital Market







Decomposition Analysis PartitionByMarket	Index	G(%)	T(%)
	Within	0.570 (49.22)	0.637 (46.36)
	Between	0.588 (50.78)	0.736 (53.64)

APPENDIX E: Serum Lipid Reducing Agent

E3-1: Gemfibrozil 300mg -Popular Brand in Primary, Secondary and Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	33	0.71	1.50	0.941	0.182	0.194	0.934	826600	1200	140000	9.339	0.618	0.703
Secondary	5	0.71	1.34	0.940	0.259	0.275	0.850	460000	22000	150000	0.711	0.327	0.306
Tetiary	5	0.77	1.24	0.972	0.193	0.198	0.962	1181500	110000	382500	0.700	0.499	0.531







APPENDIX E: Serum Lipid Reducing Agent

E3-2: Gemfibrozil 300 mg -Brand A in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	0.67	1.70	1.098	0.507	0.462	1.139		
Quantity	107000	15000	25000						
MAC	5	0.000	1.552	0.688				0.479	0.483





APPENDIX E: Serum Lipid Reducing Agent

E3-3: Gemfibrozil 300 mg -Brand B in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	0.74	0.76	0.755	0.010	0.013	0.756		
Quantity	29500	4000	10000						
MAC	4	0.000	0.048	0.012				0.750	1.386





APPENDIX E: Serum Lipid Reducing Agent

E3-4: Gemfibrozil 300mg -Brand C in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	0.72	2.00	1.313	0.551	0.420	0.964		
Quantity	95500	2500	58000						
MAC	4	0.000	2.45	1.451				0.385	0.370





APPENDIX E: Serum Lipid Reducing Agent

E3: Gemfibrozil 300mg -Popular Brand, Brand A, Brand B, Brand C in Primary Hospital Market

Brand	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Popular	33	0.71	1.50	0.941	0.182	0.194	0.934	826600	1200	140000	9.339	0.618	0.703
Brand A	5	0.67	1.70	1.098	0.507	0.462	1.139	107000	15000	25000	0.688	0.479	0.483
Brand B	4	0.74	0.76	0.755	0.010	0.013	0.756	29500	4000	10000	0.012	0.750	1.386
Brand C	4	0.72	2.00	1.313	0.551	0.420	0.964	95500	2500	58000	1.451	0.385	0.370





APPENDIX E: Serum Lipid Reducing Agent

E3: Gemfibrozil 300mg -Popular Brand, Brand A, Brand B, Brand C in Primary Hospital Market





Decompositon Analysis PartitionByBrand InPrimaryMarket		
	G(%)	T(%)
Within	0.594 (46.62)	0.709 (51.23)
Between	0.680 (53.38)	0.675 (48.77)

APPENDIX E: Serum Lipid Reducing Agent

E4: Gemfibrozil 600 mg -Popular Brand in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	1.60	2.50	1.915	0.399	0.208	2.337		
Quantity	88500	5500	70000						
MAC	4	0.000	5.207	3.232				0.320	0.303





APPENDIX E: Serum Lipid Reducing Agent

E5-1: Simvastatin 10mg -Popular Brand in Primary, Secondary and Tertiary Hospital Market







Decomposition Analysis PartitionByMarket	Index	G(%)	T(%)
	Within	0.501 (56.28)	0.453 (51.90)
	Between	0.390 (43.72)	0.420 (48.10)

APPENDIX E: Serum Lipid Reducing Agent

E5-1: Simvastatin 10mg -Popular Brand in Primary, Secondary and Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	15	0.86	5.70	2.424	1.403	0.579	2.381	150300	600	30000	8.825	0.557	0.542
Secondary	7	1.26	2.66	2.051	0.477	0.232	1.996	482450	24000	110000	0.601	0.464	0.413
Tetiary	12	0.86	8.38	2.328	2.031	0.873	1.513	1743970	25920	762000	16.080	0.454	0.365







APPENDIX E: Serum Lipid Reducing Agent

E5-2: Simvastatin 10 mg -Brand A in Primary Hospital Market

Tertiary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	17	1.61	5.00	3.015	1.285	0.426	2.243		
Quantity	416000	1000	95000						
MAC	17	0.000	65.849	10.158				0.762	1.251





APPENDIX E: Serum Lipid Reducing Agent

E5-3: Simvastatin 10 mg -Brand B in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	11	1.20	3.00	2.247	0.615	0.274	2.110		
Quantity	45300	900	9300						
MAC	11	0.000	2.582	0.648				0.453	0.382





APPENDIX E: Serum Lipid Reducing Agent

E5-4: Simvastatin 10 mg -Brand C in Primary Hospital Market

Secondary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	1.28	8.56	4.096	2.911	0.711	2.394		
Quantity	93000	2100	52200						
MAC	5	0.000	24.381	12.149				0.464	0.452





APPENDIX E: Serum Lipid Reducing Agent

E5: Simvastatin 10 mg -Popular Brand, Brand A, Brand B, Brand C in Primary Hospital Market

Brand	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Popular	15	0.86	5.70	2.424	1.403	0.579	2.381	150300	600	30000	8.825	0.557	0.542
Brand A	17	1.61	5.00	3.015	1.285	0.426	2.243	416000	1000	95000	10.158	0.762	1.251
Brand B	11	1.20	3.00	2.247	0.615	0.274	2.110	45300	900	9300	0.648	0.453	0.382
Brand C	5	1.28	8.56	4.096	2.911	0.711	2.394	93000	2100	52200	12.149	0.464	0.452





APPENDIX E: Serum Lipid Reducing Agent

E5: Simvastatin 10 mg -Popular Brand, Brand A, Brand B, Brand C in Primary Hospital Market





Decompositon Analysis PartitionByBrand InPrimaryMarket		
	G(%)	T(%)
Within	0.596 (45.61)	0.747 (40.16)
Between	0.711 (54.39)	1.113 (59.84)

APPENDIX E: Serum Lipid Reducing Agent

E6-1: Simvastatin 20 mg -Popular Brand in Primary, Tertiary Hospital Market





APPENDIX E: Serum Lipid Reducing Agent

E6-1: Simvastatin 20 mg -Popular Brand in Primary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Primary	8	3.07	12.48	5.746	3.088	0.537	4.779	47700	600	18000	5.900	0.520	0.491
Tetiary	4	2.35	6.42	4.103	1.821	0.444	3.792	420000	42000	240000	1.935	0.572	0.644







APPENDIX E: Serum Lipid Reducing Agent

E6-2: Simvastatin 20 mg -Brand A in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	4	3.00	5.00	4.090	0.864	0.211	3.777		
Quantity	67800	9900	33000						
MAC	4	0.000	0.813	0.494				0.367	0.349





APPENDIX E: Serum Lipid Reducing Agent

E7: Simvastatin 40 mg -Popular Brand in Secondary Hospital Market

Secondary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	4.34	10.70	6.870	2.437	0.355	6.224		
Quantity	332250	6300	117000						
MAC	5	0.000	6.624	2.972				0.517	0.574





APPENDIX E: Serum Lipid Reducing Agent

E8: Simvastatin 80 mg -Single Brand in Secondary, Tertiary Hospital Market





APPENDIX E: Serum Lipid Reducing Agent

E8: Simvastatin 80 mg -Single Brand in Secondary, Tertiary Hospital Market

Market	n	Pmin	Pmax	Pmean	SD	CV	WAP	Qtotal	Qmin	Qmax	MAC	Gini	Theil
Secondary	5	33.88	34.95	34.736	0.479	0.014	34.511	78300	1800	32100	0.006	0.800	1.609
Tetiary	6	34.95	34.95	34.950	0.000	0.000	34.950	87000	5850	29700	0.000	0.000	0.000







APPENDIX E: Serum Lipid Reducing Agent

E9: Fenofibrate 300 mg -Popular Brand in Primary Hospital Market

Primary	n	Min.	Max.	Mean	SD	CV	WAP	Gini	Theil
Price	5	12.00	12.84	12.504	0.460	0.037	12.211		
Quantity	37400	2000	19000						
MAC	5	0.000	0.143	0.057	0.08			0.600	0.916





APPENDIX F

APPENDIX F: MULTIPLE REGRESSION ANALYSIS ASSUMPTION TEST

1. Normality

Histogram

Dependent Variable: G



Scatterplot

Dependent Variable: G



2. Linearlity





3. Mulitcollinearity

There was no the problem of multicollinearity according to the criteria; tolerance < 0.19 or VIF > 5.3.

Coefficients(a)

Model		Unstandardized Coefficients		Standardized Coefficients	t	Sig.	Correlations			Collinearity Statistics	
		B	Std. Error	Beta			Zero-order	Partial	Part	**Tolerance**	**VIF**
1	(Constant)	.409	.034		11.885	.000					
	PRIMARY	.075	.046	.170	1.628	.106	.138	.145	.145	**.726**	**1.376**
	Secondary	.030	.049	.063	.600	.550	-.026	.054	.053	**.726**	**1.376**
2	(Constant)	.402	.090		4.451	.000					
	PRIMARY	.169	.058	.385	2.909	.004	.138	.258	.255	**.439**	**2.279**
	Secondary	.052	.050	.110	1.041	.300	-.026	.095	.091	**.691**	**1.447**
	#AvailableBrands	-.008	.006	-.169	-1.196	.234	-.072	-.109	-.105	**.386**	**2.591**
	MKTCONC	9.682E-09	.000	.145	1.460	.147	.122	.133	.128	**.775**	**1.290**
	Popularity	.000	.001	.046	.332	.741	.051	.030	.029	**.400**	**2.503**
	AdjMktPower	-.019	.034	-.056	-.561	.576	-.079	-.051	-.049	**.759**	**1.318**
3	(Constant)	.431	.145		2.963	.004					
	PRIMARY	.161	.059	.366	2.705	.008	.138	.244	.238	**.424**	**2.357**
	Secondary	.046	.050	.097	.906	.367	-.026	.084	.080	**.680**	**1.470**
	#AvailableBrands	-.006	.006	-.136	-.941	.349	-.072	-.087	-.083	**.373**	**2.682**
	MKTCONC	9.183E-09	.000	.138	1.261	.210	.122	.116	.111	**.650**	**1.539**
	Popularity	6.687E-05	.001	.010	.058	.954	.051	.005	.005	**.245**	**4.074**
	AdjMktPower	-.026	.034	-.076	-.747	.457	-.079	-.069	-.066	**.741**	**1.350**
	ED/NED	.022	.073	.037	.305	.761	-.064	.028	.027	**.520**	**1.921**
	IMGEN	.032	.094	.045	.339	.735	.101	.031	.030	**.439**	**2.278**
	LOCALGEN	-.049	.082	-.108	-.593	.554	-.153	-.055	-.052	**.232**	**4.303**

a Dependent Variable: G

There was no the problem of multicollinearity according to the criteria; variance proportion> 90%.

Collinearity Diagnostics(a)

Model	Dimension	Eigenvalue	Condition Index	Variance Proportions									
				(Constant)	Primary	Secondary	#AvailableBrands	Mkt.conc.	Popularity	Mkt.Power	ED/NED	IMGEN	LOCALGEN
1	1	1.831	1.000	.08	.07	.06							
	2	1.000	1.353	.00	.19	.29							
	3	.169	3.291	.92	.74	.65							
2	1	4.167	1.000	.00	.01	.01	.01	.01	.00	.01			
	2	1.426	1.710	.00	.05	.06	.02	.11	.01	.00			
	3	.778	2.315	.00	.01	.30	.00	.38	.00	.00			
	4	.309	3.672	.01	.00	.25	.09	.48	.13	.00			
	5	.192	4.653	.00	.73	.22	.13	.00	.01	.16			
	6	.097	6.548	.01	.07	.07	.56	.02	.12	.68			
	7	.031	11.615	.98	.13	.09	.20	.01	.73	.14			
3	1	5.812	1.000	.00	.00	.00	.00	.00	.00	.00	.00	.00	.00
	2	1.520	1.955	.00	.03	.06	.01	.10	.01	.00	.00	.00	.00
	3	.999	2.412	.00	.00	.00	.00	.02	.00	.00	.00	.34	.01
	4	.820	2.663	.00	.03	.27	.00	.25	.00	.00	.00	.00	.00
	5	.310	4.330	.00	.02	.32	.10	.33	.07	.00	.00	.00	.00
	6	.214	5.212	.00	.60	.23	.01	.08	.03	.02	.03	.05	.05
	7	.162	5.994	.00	.12	.01	.21	.13	.01	.26	.06	.04	.09
	8	.094	7.876	.00	.08	.07	.61	.01	.08	.66	.00	.01	.00
	9	.056	10.160	.00	.00	.00	.00	.00	.01	.00	.84	.34	.48
	10	.013	21.259	.99	.13	.05	.06	.08	.80	.05	.07	.20	.36

a Dependent Variable: G

BIOGRAPHY

NAME: Miss Siripa Udomaksorn

BIRTH DAY: April 6, 1974

BIRTH PLACE: Trang

EDUCATION:

- Bachelor Degree of Pharmaceutical Sciences, Prince of Songkla University, Since 1996
- Master Degree of Business Administration (MBA), Price of Songkla University, Since 2001

CURRENT CAREER:

Faculty Member,
Department of Pharmacy Administration,
Faculty of Pharmaceutical Sciences
Prince of Songkla University